Pharmaceutical research and development a breakthrough point constraint management mechanism.doc

 PAGE \* MERGEFORMAT 9 Pharmaceutical research and development a breakthrough point constraint management mechanism Short-term ‘worse’? January 16 of this year, one of the world’s top ten pharmaceutical companies to enter China for almost ten years in China, Switzerland, Roche announced the establishment of a fifth of its global R amp;amp; D centers. It was learned that R amp;amp; D center will be built and put into operation by the end of 2004, completed the first year will be about 40 to 50 scientists in the new R amp;amp; D centers. Roche is the second Novo Nordisk, AstraZeneca, Eli Lilly, Servier, the fifth R amp;amp; D centers in China cross-border pharmaceutical companies. The face of the domestic pharmaceutical giants in the country’s big snatch the domestic talent, but is reminiscent of many years of study abroad do not want to return to the effectiveness of Chinese students. Well-known reasons, of course, outstanding foreign entrepreneurial environment and excellent R amp;amp; D platform. For such people a variety of comments on the phenomenon of incessant mixed. However, ‘from foreign pharmaceutical giants to set up R amp;amp; D centers in China, for Chinese enterprises, especially pharmaceutical R amp;amp; D system, Chinese companies will undoubtedly have a strong role in promoting reform. ‘An industry express optimism. And this promotion is a more meaningful interpretation of foreign R amp;amp; D Center R amp;amp; D system and management system should be the most worthy of the domestic pharmaceutical companies to study and learn from them. China is not shortage of skilled research personnel, lacking is a mechanism and an incentive. The face of foreign terms is relatively generous compensation and R amp;amp; D environment, it is difficult to prevent the domestic R amp;amp; D personnel echocardiography. ‘In China, the majority of pharmaceutical companies in the chemical drugs, their ability to innovate is very defective, and can not be made avail